Earnings Releases·Nov 12, 2026, 8:00 AM ET

IMUNON — Third Quarter 2026 Earnings Summary

Net loss for Q3 2026 was $3.8 million ($0.64/share), an improvement from $3.4 million ($1.16/share) in Q3 2025; nine-month net loss reached $10.9 million ($2.01/share) versus $10.3 million ($5.53/share) in the prior year period.
Operating expenses remained largely flat year-over-year, with Q3 2026 at $3.4 million compared to $3.5 million in 2025, while R&D expenses decreased slightly in Q3 but increased for the nine-month period.
The Company executed a capital structure optimization on September 29, 2026, by converting $1.2 million of debt and accrued interest into Series B Preferred Stock, reducing the A-1 Note balance by 43% and increasing stockholders' equity to $2.6 million.
Strategic progress includes the sale of ThermoDox® rights to VoxelDox Therapeutics for up to $16.5 million in contingent milestones and royalties, alongside an NCI CRADA to support IMNN-001 development, with Phase 3 OVATION 3 enrollment expected to conclude by Q1 2029.
Cash and cash equivalents stood at $4.0 million with an additional $5.0 million in restricted cash as of September 30, 2026, while the Company filed a Form S-1 for a proposed securities offering on October 27, 2026.